Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Oncology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Oncology Other
    ATA Publishes Revised Guidelines for Managing Thyroid Cancer - (DGNews)
    Brain Tumours In Childhood Leave a Lasting Mark On Cognition, Life Status - (DGNews)
    Patients With Diverticulosis May Require Less Aggressive Screening for Colonic Polyps: Presented at ACG - (DGDispatch)
    High Definition Colonoscopy Increases Polyp Detection: Presented at ACG - (DGDispatch)
    Ascorbic Acid-Based Prep Improves Bowel Cleansing, Increases Small Adenoma Detection Rate During Colonoscopy: Presented at ACG - (DGDispatch)

    News archive

     Recent webcasts/CME - Oncology Other
    • Questioning Clinical Assumptions in Accelerated-Phase and Blast-Crisis CML
    • Carcinoid Tumors of the Gastrointestinal Tract
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents
      Multidisciplinary Approach to Management of Neuroendocrine Tumors
      Cancer and Venous Thromboembolism: Current Clinical Issues

      Webcasts/CME archive

       Recent cases - Oncology Other
        Giant Thoracic Schwannoma Presenting with Abrupt Onset of Abdominal Pain: A Case Report
        Novel Deployment of a Covered Duodenal Stent in Open Surgery to Facilitate Closure of a Malignant Duodenal Perforation
        Clinical Experience of Novel Interconnected Porous Hydroxyapatite Ceramics for the Revision of Tumor Prosthesis: A Case Report
        Superior Vena Cava (SVC) Reconstruction Using Autologous Tissue in Two Cases of Differentiated Thyroid Carcinoma Presenting with SVC Syndrome
        Surgical Treatment of a Giant Tibial High-Grade Mixofibrosarcoma with Preservation of Limb Function: A Case Report

        Cases archive
          




        my personal edition > oncology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        A 2-Week-On, 2-Week-Off Schedule Appears Optimal for BIBW 2992 in Advanced Solid Tumors: Presented at AACR-NCI-EORTC

        By Maggie Schwarz

        PHILADELPHIA, PA -- November 21, 2005 -- The investigational agent BIBW 2992 at a dose of 70 mg appears safe in patients with solid tumors and the adverse effects can be easily controlled with loperamide and minocycline, according to a phase 1 and pharmacological dose escalation study.

        Ferry ALM Eskens, MD, PhD, Professor of Clinical Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands, presented the results on November 16th at the International Conference on Molecular Targets and Cancer Therapeutics.

        The conference was organized jointly by the American Association for Cancer Research, National Cancer Institute, and the European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC).

        BIBW 2992 is a highly selective potent irreversible dual inhibitor of the intracellular tyrosine kinase activity of epidermal growth factor receptor 1 (EGFR-1) and 2 (HER2). It inhibits EGF-induced receptor phosphorylation and cellular proliferation in the low nanomolar range.

        Dr. Eskens and colleagues enrolled patients with advanced solid tumors to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of BIBW 2992 administered once daily (OD) for 14 days followed by 14 days off treatment. The also evaluated results for preliminary evidence of anti-tumor activity.

        He presented the results of the ongoing study in 34 patients enrolled so far. Median patient age was 57 years, and ranged from 18 to 80 years.

        Patients had a histologically or cytologically confirmed diagnosis of solid malignant tumor that was refractory to standard therapies. Preferably patients with tumours historically known to express EGFR and/or HER2 were eligible.

        Patients were treated for 2 weeks followed by a 2-week rest. These cycles could be repeated if the patient was not progressing. Patients with stable disease after 6 courses of treatment were allowed to continue in an extension study.

        No complete or partial responses were seen, but seven patients had stable disease that lasted 4 four or more courses of treatment.

        Dose-limiting toxicity consisted of skin toxicity and diarrhea. The investigators recommended a 70 mg dose, at which diarrhea and skin toxicity can be controlled using loperamide and minocycline.

        They concluded that BIBW 2992 was safe in patients given a 2-week-on, 2-week-off schedule.


        [Presentation title: A Phase I Dose Escalation Study of BIBW 2992, an Irreversible Tyrosine Kinase Inhibitor of Epidermal Growth Factor Receptor 1 (EGFR-1) and 2 (Her2) in a 2 Week on 2 Week off Schedule in Patients with Advanced Solid Tumors. Abstract A235]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send